Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Prasugrel Beats Plavix In TRITON, But Bleeding Data Raise Questions

Executive Summary

Eli Lilly released powerful efficacy results from an eagerly anticipated Phase III head-to-head trial of its experimental antiplatelet agent prasugrel, which has the potential to take market share from Bristol-Myers Squibb's blockbuster Plavix (clopidogrel)

You may also be interested in...



Prasugrel Could Avoid More Restrictive REMS Options, Lilly Hints

Should a risk management and evaluation strategy accompany approval of Lilly's anti-platelet drug prasugrel, the product may escape the most burdensome REMS options, Lilly hinted during its July 24 earning call

Prasugrel Could Avoid More Restrictive REMS Options, Lilly Hints

Should a risk management and evaluation strategy accompany approval of Lilly's anti-platelet drug prasugrel, the product may escape the most burdensome REMS options, Lilly hinted during its July 24 earning call

Lilly/Daiichi Submit Prasugrel; Showdown With Plavix Timed For Second Half

Lilly and Daiichi Sankyo plan to launch the antiplatelet drug prasugrel immediately after it is approved, supported by an extensive sales force including representatives from both companies

Related Content

UsernamePublicRestriction

Register

PS049002

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel